Shares of Cytori Therapeutics (CYTX) are up 25% in pre-market trading after the company announced this morning that its exclusive licensee, Lorem Vascular, has been granted regulatory clearance for the Cytori Celution System by the State FDA of the People’s Republic of China.
Cytori Therapeutics said that this regulatory clearance officially makes its Celution System available in the largest healthcare market in the world and triggers a substantial 2015 product purchase order for Cytori from Lorem Vascular.
Today’s news marks the first time that Cytori’s Celution System has gained any level of access to the mainland Chinese healthcare market. Lorem Vascular will begin product launch of Celution in key hospitals in China immediately.
CYTX shares recently gained 0.29 to $1.45. The stock is down more than 58.12% year-over-year and has gained roughly 137% year-to-date. In the past 52 weeks, shares of San Diego, California-based biotechnology company have traded between a low of $0.36 and a high of $2.75.
Fundamentally, CYTX shows the following financial data:
- $14.62 million in cash in most recent quarter
- $38.72 million t-12 total assets
- ($5.7) million total equity
- $7.60 million t-12 revenue
- ($38.54) million annual net income
- ($31.09) million free cash flow
On valuation measures, Cytori Therapeutics Inc. shares have a T-12 price/sales ratio of 16.66. EPS is ($0.47). The name has a market cap of $125.49 million and a median Wall Street price target of $6.00 with a high target of $7.00. Currently there are 3 analysts that rate CYTX a ‘Buy’. No analyst rates it a ‘Hold’ or a ‘Sell’.
In terms of share statistics, Cytori Therapeutics Inc. has a total of 92.45 million shares outstanding with 17.02% held by insiders and 18.40% held by institutions. The stock’s short interest currently stands at 20.21%, bringing the total number of shares sold short to 15.00 million.
Cytori Therapeutics, Inc. closed Thursday at $1.16. The name has a total market cap of $125.49 million.